- Analysis
- Barani Krishnan
- 32
ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is headquartered in Siheung-si, South Korea.
Metrics to compare | 237690 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship237690PeersSector | |
---|---|---|---|---|
P/E Ratio | 58.1x | 8.5x | −0.6x | |
PEG Ratio | 0.32 | 0.01 | 0.00 | |
Price/Book | 3.9x | 1.0x | 2.6x | |
Price / LTM Sales | 6.8x | 0.6x | 3.1x | |
Upside (Analyst Target) | 45.9% | 49.5% | 48.2% | |
Fair Value Upside | Unlock | 23.4% | 8.0% | Unlock |